Trademarkia Logo

Canada

C$
NEXVOUND
APPROVED

on 20 Mar 2025

Last Applicant/ Owned by

Eli Lilly and Company

Lilly Corporate CenterIndianapolis, IN 46285

US

Serial Number

2348575 filed on 10th Sept 2024

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

NEXVOUND

Trademark usage description

pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for diagnosing and treating neu Read More

Classification Information


Class [005]
Pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; pharmaceutical preparations for the prevention and treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain; pharmaceutical preparations for the treatment and the prevention of dementia; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections.; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, Crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, ulcerative colitis; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders, and neuromuscular diseases, namely primary periodic paralysis; pharmaceutical preparations for the treatment of endocrine diseases, namely, glucagonoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of mental health disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for treatment of coronavirus;


Classification kind code

12

Mark Details


Serial Number

2348575

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 27
on 20th Mar 2025
Approval Notice Sent
Submitted for opposition 26
on 20th Mar 2025
Approved
Submitted for opposition 22
on 12th Mar 2025
Search Recorded
Submitted for opposition 287
on 26th Sept 2024
Pre-Assessment Letter Sent
Submitted for opposition 30
on 10th Sept 2024
Filed
Submitted for opposition 1
on 10th Sept 2024
Created
Submitted for opposition 31
on 10th Sept 2024
Formalized